the human PrmIP and the IP promoter sequences from all other non-primates is low but that part of the URR, encompassing the PU.1(b) and C/EBP elements, represents the most highly conserved promoter region across all species examined 31 .
The pluripotent HEL92.1.7 cell line can undergo differentiation into the more platelet-like lineage in response to a host of physiologic and/or experimental cell differentiating agents including cytokines, growth factors or phorbol esters, such as phorbol myristic acid (PMA) 56 . During such cell differentiation, there is a concomitant increase in the expression of platelet proteins including the human IP and the T prostanoid receptor/TP. While Wilms tumour (WT) 1, early growth response (Egr) 1 and SpI were identified as the key factors responsible for the regulated expression of TP gene expression during such megakaryblastic differentiation 57 , detailed characterization of the PrmIP identified two key PMAresponsive regions (PRRs) that regulate IP/PTGIR expression in response to PMA-induced differentiation of HEL cells 31 . More specifically, PRR1 maps to the URR within PrmIP4 while PRR2 is located within the "core promoter" region, contained within PrmIP6. Through a combination of approaches, it was established that while C/EBPδ can bind to the URR/PRR1 region under basal conditions to repress IP/PTGIR expression in HEL cells, following PMA-induced differentiation C/EBPδ repression is lifted and coincides with enhanced binding of PU.1 to its cis-acting elements within the UAR/PRR1 region 31 . Furthermore, in response to PMA-induced differentiation, there is also enhanced binding of the key transacting factors required for basal expression of the PTGIR, namely Sp1, PU.1 and Oct-1, to the PRR2 that maps to the "core region" of PrmIP/PrmIP6, further supporting or facilitating the PMA-induced increase in IP expression that occurs following PMA-induced differentiation of HEL cells 31 . Hence, collectively, the increased expression of the IP that occurs during PMA-induced differentiation of HEL cells involves the combined action of PMA-induced (a) alleviation of binding of/repression by C/EBPδ and enhanced binding of PU.1 to the URR/PRR1 region and (b) through enhanced binding of Sp1, PU.1 and Oct-1 to the PRR2 that maps to the core promoter region of the PTGIR (Figure 3 ) 31 .
C/EBPβ and C/EBPδ are known to act synergistically to regulate transcription of various genes involved in immune and inflammatory responses 58 . Interestingly, COX2, primarily involved in prostanoid generation in response to inflammation, has been identified as a transcriptional target of both C/EBPβ and C/EBPδ 59 . During the initial stage of its induction, C/EBPβ, along with cAMP response binding protein (CREB), plays a major role in the transcriptional up-regulation of the COX2 gene (PTGS2). Thereafter, C/EBPδ along with the transcriptional co-activator p300 and several other factors are subsequently recruited into a complex to sustain COX2 expression 59 . Therefore, both C/EBPβ and C/EBPδ are critical transcriptional regulators of genes involved in prostanoid biosynthesis and function, including the COX2/ PTGS2 and IP/PTGIR genes. Mechanistically, in the case of the PTGIR, as the megakaryoblastic HEL cells undergo differentiation to the more platelet-phenotype there is a switch in transcription factor binding from predominantly C/EBPδ binding to the URR to predominantly PU.1 binding to the PMAinduced PRR1 region to increase IP expression and signalling following cellular differentiation 31 .
Transcriptional Regulation of PTGIR by Estrogen:
In addition to that of prostacyclin, the protective role of estrogens in the myocardium and vasculature have also been categorically established being associated with gender-specific differences in the occurrence of coronary artery disease (CAD) and with lower incidence of stroke and other CV events in pre-menopausal women retarding atherogenesis and improving endothelial function [60] [61] [62] . On average, women develop vascular disease 10 years later than men and this has been attributed to the protective effects of the female sex hormones, particularly the estrogens, while in the estrogen-deplete post-menopausal woman such gender differences disappear. The importance of estrogen is also strongly supported by observations in younger women with premature ovarian failure (POF) who display a higher risk of premature death, particularly due to CV disease 60 . Furthermore, hormone/estrogen replacement therapy can prevent the primary onset of CAD in post-menopausal women 61 , although such effects are not without controversy 63, 64 .
The effects of estrogen are largely mediated through its binding to one of two estrogen receptor (ER) and  isoforms, members of the nuclear receptor superfamily 65 . ER and ER display distinct patterns of expression and function in various tissues but both act as ligand-dependent transcriptional regulators either by direct binding to the estrogen-responsive element (ERE) with the consensus palindromic repeat (5'-GGTCAnnnTGACC-3'), or indirectly by interacting with other transcription factors, such as Sp1 and Ap1, and by recruitment of its co-activators and/or co-repressors 65, 66 .
In addition to its classic genomic regulation, estrogen can mediate more rapid non-genomic effects such as through activation of GPR30, a member of the G protein coupled receptor superfamily 67 . Moreover, it is now also accepted that many of its CV protective actions are actually mediated by direct effects on the blood vessel wall maintaining endothelium function and regulating plasma lipids 60-62 . For example, estrogen increases the synthesis & release of the endothelial-derived vasodilators and antiplatelet agents nitric oxide and prostacyclin and, in situations of vascular injury, impairs expression of a host of pro-inflammatory mediators including C-reactive protein 61, 62 . More specifically, in the case of prostacyclin, estrogen increases the expression of its biosynthetic enzymes COX1, COX2 and prostacyclin synthase, resulting in up to 3-fold increases in systemic prostacyclin levels in rodents 68 . Moreover, in the female atherosclerotic-prone low density lipoprotein receptor null mouse (LDLR -/-), estrogen increased both COX2 expression and prostacyclin generation in the ovariectomized animal resulting in substantial atheroprotection 69 . However, in the same study, further disruption of the IP (PTGIR) gene completely abrogated the atheroprotective effects of estrogen and accelerated atherogenesis in the double LDLR -/-/IP -/null mouse 69 , providing compelling evidence that many of the protective actions of estrogen within the CV system are indeed mediated by prostacyclin and its receptor, the IP. In fact, owing to those findings, through retrospective epidemiologic studies, that group provided evidence to suggest that NSAIDs and, in particular, selective COX2 inhibitors COXIBs that impair prostacyclin synthesis, may undermine the cardioprotective effects of estrogen replacement therapy in peri-menopausal women 70 . However, despite such findings in both pre-clinical models and from observational studies in humans, the actual mechanistic basis of the role of the IP in mediating such estrogen-induced atheroprotection was unknown including, for example, whether estrogen may directly or indirectly regulate IP expression levels to account for such effects.
In the context of the latter, in studies investigating the key factors regulating expression of the human IP/PTGIR gene within the human vasculature 29 , we discovered that the PrmIP contains a near perfect estrogen response element (ERE; 5' -GGTCAaggTCACC-3') which is also evolutionary conserved in other higher species orthologues. The frequency, proximity and conservation of the near classic ERE within the PrmIP led us to hypothesize that the PTGIR might indeed be directly regulated by estrogen which, in theory, might explain some of the combined cardioprotective and anti-thrombotic effects of estrogen and prostacyclin within the vasculature. In addressing this, we established that physiologic concentrations of estrogen (17-estradiol) led to increased human IP mRNA and functional receptor expression and to increased PrmIP-directed gene expression in vascular endothelial (EA.hy926, 1 o HUVECs) and megakaryoblastic (HEL 92.1.7) cells and in 1° hAoSMCs (Figure 4) 30 . Moreover, this estrogen-regulation of the human IP occurred through a transcriptional mechanism involving direct binding of ERα, but not ERβ, to the evolutionary conserved ERE located within an upstream steroid regulatory region of PrmIP 30 . Whether ERβ may regulate PTGIR gene expression in a cell type-specific manner or, indeed, whether it may act as a competitor of ERα-regulated expression of the IP, as occurs in the case of the BRCA2 gene 71 , requires further investigation.
Collectively, these data established that ERα serves as a trans-acting factor critical for regulation of the IP expression in response to estrogen and occurs through a direct "estrogen-ERα-ERE" mechanism. It is proposed that such regulation of IP expression may provide a mechanism, at least in part, to explain the combined effects of prostacyclin and the female hormone estrogen in protecting against CVD in younger estrogenic women 72, 73 .
Transcriptional Regulation of PTGIR by Cholesterol:
Elevated LDL-cholesterolemia is a well-recognized risk factor in CVD 74, 75 . In addition to estrogen, the clinical benefits of low serum LDL-cholesterol in the prevention of CAD are also widely recognized and can, in part, be accounted for by improvements in endothelial-dependent vasodilation by prostacyclin and nitric oxide 76 . For example, Statins yield pleiotropic beneficial effects not associated with their cholesterol-lowering properties 77, 78 , most notably improved cerebral blood flow associated with enhanced nitric oxide generation 79, 80 . Analysis of the effects of cholesterol and fatty acids on hepatic gene expression led to the discovery of a family of membrane-bound transcription factors named sterol response element binding proteins or SREBPs and identified them as the master regulators of lipid homeostasis 81 . SREBPs are members of the bHLH-LZ class of transcription factors and bind as dimers to a direct repeat "E-box" element referred to as a sterol response element (5'-ATCACCCCAC-3') 82 . The first well-characterized functional sterol response element (SRE) was that of the human LDL receptor gene promoter 83 , which was then used for affinity purification and subsequent cloning of the SREBP trans-acting factor 84 . Family members SREBP1a and SREBP1c are known to activate genes involved in regulating general lipid metabolism, whereas SREBP2 regulates expression of genes involved in cholesterol homeostasis 81, 85 . SREBPs often cooperate with other DNA-binding proteins to achieve maximal transcriptional activation. For example, NF-Y and CREB cooperate with SREBP1 to regulate the HMG-CoA reductase gene, whereas SREBP1 cooperates with Sp1 to activate the LDL receptor gene 86-88 . Furthermore, SREBP1 and Sp1 have been identified as the two major transcription activators of the fatty acid synthase gene (FASN), one of the key enzymes in fatty acid synthesis 89 . Critically, regulation by these additional trans-acting factors permits modulation of SREBP's transcriptional activity independently of its sterol-regulated proteolytic processing.
Although numerous transcriptional targets of SREBPs have been identified, little is known about their effects on expression of genes in extra-hepatic tissues or genes not directly associated with lipid homeostasis. The finding that endothelial prostacyclin levels may be increased by the cholesterolresponsive SREBP1 through its transcriptional up-regulation of COX2 was the first demonstration that the SREBP-mediated pathway(s) are present in vascular tissue 90, 91 . Reductions in LDL-cholesterol increase prostacyclin generation in endothelial cells by the selective transcriptional up-regulation of COX2, but not COX1 or prostacyclin synthase, and this occurs through binding of the cholesterolresponsive transcription factor SREBP to a SRE within the COX2 promoter 90, 91 . Through recent studies investigating the factors regulating the expression of the IP/PTGIR within the vasculature, it was discovered that IP expression may also be up-regulated in megakaryoblastic HEL and endothothelial (EA.hy 926 and 1 o HUVECs) cells cultured under low-serum cholesterol conditions ( Figure 5) 92 . Through detailed mechanistic studies, it was established that this up-regulation of IP expression occurs through a transcriptional mechanism involving binding of the cholesterol-responsive trans-acting factor SREBP1a, but not SREBP2, to a near-perfect evolutionary conserved SRE within the PrmIP (5' CTCACCCAG 3') 92 . Critically, it was established that the functional SRE is located immediately downstream/3' of the Sp1, PU.1 and Oct-1 cis-acting elements within the "core promoter" region, and that binding of Sp1 to its cis-element participates in SREBP1-binding to the SRE and in regulating PTGIR expression in response to low serum cholesterol 92 . These data are in keeping with previous studies showing SREBP1-dependent, but not SREBP2-dependent, transactivation of the LDLR and COX2 promoters and with the fact that SREBP1 is the predominant form expressed in endothelial cells 90, 93 .
Hence, discovery of the transcriptional regulation of the PTGIR by the cholesterol-responsive master regulator SREBP1 is significant and, mechanistically, may not only explain many of the protective roles of the prostacyclin-IP axis within the vasculature but may also explain, at least in part, some of pleiotropic benefits of low-serum cholesterol and of cholesterol-lowering agents in improving/protecting vascular function. Furthermore, the fact that the human IP is also up-regulated by low-serum cholesterol in the platelet progenitor HEL cells suggests that low-serum cholesterol or cholesterol-lowering agents may also elevate IP expression in platelets, thereby conferring added anti-thrombotic benefits over-andabove the endothelial benefits in reducing overall risk of CAD. Collectively, these studies have led to significant advancements into elucidating the mechanisms of transcriptional regulation of the PTGIR within the human vasculature under both basal conditions and in response to cellular differentiation 29 92 30 31 . Furthermore, they provide an important molecular and genetic platform for understanding the role of the prostacyclin-IP as a protective axiom within the vasculature and in mediating, at least in part, the cardio-protective effects of estrogen 30 and of reduced serum-cholesterol 92 .
Regulation of IP Signalling through Novel Protein:Protein Interactions:
As stated, the main physiologic actions of prostacyclin are mediated through the IP 2, 3 , a member of the GPCR superfamily that primarily couples to Gs/adenylyl cylase activation but also to other effectors in a cell-and/or species-specific manner 94, 95 . The IP is somewhat unusual among GPCRs in that it undergoes isoprenylation and palmitoylation within its carboxyl-terminal tail (C-tail) domain, modifications critical for IP signalling and function 96-100 . More specifically, the human IP undergoes farnesylation at Cys 383 within its carboxy-terminal conserved -C 383 SLC 386 , or 'CaaX', motif 99, 100 and palmitoylation at Cys 308 , Cys 309 , and Cys 311 (Figure 6) 97, 98 . While neither lipid modification affect the ligand binding properties of the IP, they modulate its G protein coupling/intracellular signalling and, in the case of palmitoylation, may influence its ability to directly interact with Rab11a, to regulate agonist-induced trafficking of the IP following activation 96-99 . Moreover, the IP is post-translationally modified by ubiquitination, which targets the mature and immature species to the lysosomal and 26S proteasomal/ERAD degradation pathways, respectively 101, 102 .
In addition to their classic interaction with heterotrimeric G-proteins, it is now recognized that GPCRs can interact with a wide range of functionally diverse proteins known collectively as 'GPCR interacting proteins' or 'GIPs', thereby regulating an array of other cellular events 103, 104 . Furthermore, due to its divergent sequence and capacity to contain functionally distinct binding motifs, the intracellular C-tail domain of the GPCR is the critical binding domain for such interactions between GPCRs with their specific GIP(s) [103] [104] [105] . To identify novel GIPs that interact with the IP, potentially shedding new insights into the role of prostacyclin within the vasculature including in cardioprotection, a yeast-two-hybrid (Y2H)-based screen of a human kidney cDNA library was carried out where the carboxyl (C)-terminal tail domain of the IP (IP 299-386 ) was used as the initial bait protein 96, 97, 106, 107 . Through those studies, Rab11a was identified as a direct binding partner of the IP and this IP:Rab11a interaction was found to be dependent on a 14-residue Rab11 binding domain (RBD) located within its proximal C-tail domain of the IP, comprising Val 299 -Val 307 , adjacent to its palmitoylated residues at Cys 308 -Cys 311 96, 97 . Moreover, it was established that the orientation of the RBD within the IP and its interaction with Rab11a may be regulated by agonist-dependent palmitoylation of the IP at Cys 309 >Cys 308 , to dynamically regulate the trafficking and signalling of the IP 97 . In addition, as elaborated upon further below, it was discovered that the IP also interacts with members of the multi-PDZ domain proteins PDZK1 (NHERF3) and IKEPP (NHERF4) through interactions dependent on a PDZ-ligand/binding motif within the distal C-tail region of the IP 106, 107 .
Role of PDZ Domain Proteins:
The frequently encountered postsynaptic density-95, disks large, zonula occludens-1 (PDZ) domain mediates protein:protein interactions by binding to the PDZ ligand located most typically, but not exclusively, at the extreme C termini of target proteins [108] [109] [110] . Through the formation of multiprotein complexes, PDZ interactions can participate in the coordination of key intra-and intercellular signaling systems, including intracellular routing or localization of proteins, cell polarity, as well as in the regulation of cell:cell interactions [108] [109] [110] . Structurally, the PDZ domain is composed of compact globular modules containing six anti-parallel β-strands (βA-βF) and two α-helices (αA and αB) with a highly conserved GLGF motif within its hydrophobic binding pocket that is responsible for the sequencespecific recognition of the PDZ ligand within the target protein(s). Depending on the nature of the three residues at their extreme C termini, the PDZ ligand of the target protein itself may belong to one of three classes, namely class I (Ser/Thr-X-Φ-COOH), class II (Φ-X-Φ-COOH), or class III (Asp/Glu-X-Φ-COOH), where Φ represents a hydrophobic amino acid and X can be any residue [108] [109] [110] .
Interaction of the IP with PDZK1.
As previously stated, we recently identified the multi PDZ-domain protein PDZK1 (NHERF3) as a highly specific interactant of the IP (Figure 7) 106 . The intracellular scaffold or adapter protein PDZ domaincontaining protein 1 (PDZK1) is a member of the Na + , H + exchanger regulatory family (NHERF) and is predominantly expressed in the brush border of the kidney and small intestine, in epithelial and endothelial cells, in macrophages and in the liver [111] [112] [113] . PDZK1 contains 4 PDZ domains, facilitating its binding to highly specific interacting partners [114] [115] [116] . Most notably, in the context of the CV system, through its interaction with the high density lipoprotein (HDL) scavenger receptor class B, type 1 (SR-B1), PDZK1 is essential for both reverse cholesterol transport (RCT) and for HDL-mediated vascular reendothelialization 112, 117 . Similar to prostacyclin and the IP, through its activation of SR-B1, HDL also plays an essential protective role within the CV system where it regulates re-endothelialization as well as RCT, maintaining endothelial integrity and protecting against atherosclerosis and restenosis 118, 119 . By binding to its C-terminal PDZ ligand, PDZK1 plays an essential role in maintaining SR-BI expression levels in the liver, thereby controlling HDL cholesterol levels, and is now also known to play a key role in HDL/SR-BI-regulation of EC migration, promoting re-endothelialization 117, 120, 121 . Hence, PDZK1 -/mice display both (i) marked hypercholesterolaemia due to a 95% decrease in SR-B1 expression in the liver and (ii) impaired re-endothelialization, leading to increased atherosclerosis &/or impaired vascular repair, and thus represent an important model of CV dysfunction 117 .
Since the discovery of an interaction of the IP with PDZK1, we have made significant advances in validating the interaction and in establishing that, similar to that of SR-B1, the interaction is likely to be functionally important with respect to the protective role of prostacyclin/IP within the vascular endothelium 106 . In brief, key amongst those findings include: (i) PDZK1 directly interacts with the IP involving a Class I PDZ ligand at its C-terminus; (ii) while the interaction occurs constitutively, it is dynamically regulated in response to agonist (cicaprost)-activation of the IP (Figure 7A) ; (iii) while PDZK1 did not influence overall levels of the IP, it increases its functional expression at the plasma membrane enhancing agonist binding and cAMP generation; (iv) specifically, in the context of the role of prostacyclin in re-endothelialization, both cicaprost and HDL were confirmed to promote substantial EC migration and in vitro angiogenesis, and in an augmentative manner (Figure 7B) , while (v) similar to that previously reported for the HDL/SR-B1-mediated EC responses 117 , siRNA-disruption of PDZK1 abolished cicaprost-induced EC migration and in vitro angiogenesis, and without affecting VEGFmediated responses 106 . A number of studies have suggested that prostacyclin-induced endothelial migration and angiogenesis occurs through its regulation of PPARδ, rather than through the IP per se 22, 23 . However, in those studies, iloprost was used as the IP agonist, which, unlike the highly selective IP agonist cicaprost used in our own studies 106 , is known to activate both the IP and PPARδ 3 . Moreover, in our studies, the effects of cicaprost were blocked by the IP antagonist RO1138452, confirming that the cicaprost induced EC-migration and angiogenesis are mediated through the IP rather than PPARδ 3 .
Collectively, given the role of prostacyclin throughout the CV system, identification of PDZK1 as a functionally important interactant of the IP sheds significant mechanistic insights into the protective roles of these key players, and potentially of HDL/SR-B1, in the vascular endothelium. Critically, we have discovered a novel link between the IP, PDZK1 and SR-B1, which potentially reveals new therapeutic approaches to vascular protection. However, in advance of being able to exploit such therapeutic potential, it is first necessary to understand key aspects of the IP:PDZK1 interaction, including pin-pointing the molecular interactions through detailed structural studies. Further to this, through detailed X-ray crystallography, the co-ordinates of the interaction between the IP with PDZD1 of PDZK1 have recently been solved to high resolution 122 .
Interaction of the IP with IKEPP:
The IP was also found to interact with IKEPP (intestinal and kidney enriched PDZ protein/ IKEPP/PDZK2) through binding of the class I type PDZ ligand at the C terminus of the IP with the domains PDZ domains (PDZD)1 and to a lesser extent PDZD2 of IKEPP (Figure 8) 107 . Compared to the other NHERF family members, IKEPP/NHERF4 has few known binding partners but among them include guanylyl cyclase C 123 and a range of transporters in the renal and gastrointestinal systems to regulate anion 123 and calcium secretion 124 and carnitine transport 115 .
The ability of the IP to bind both PDZK1 and IKEPP is not unusual as several other proteins can bind multiple NHERF family members 113, [125] [126] [127] . Moreover, while both IKEPP and PDZK1 possess 4 PDZ domains, their interaction with the IP differs with differential binding of the distinct PDZ domains 107 . This too is not without precedence. For example, the organic cation transporters OCTN1 and OCTN2 display different binding preferences for PDZ domains within PDZK1 and IKEPP where both OCTN proteins bind to PDZD1, PDZD2 and PDZD4 of PDZK1 but bind to PDZD1 and PDZD3 of IKEPP 115, 128, 129 . With respect to the IP, PDZK1 and IKEPP display clear structural and functional differences in their interaction and regulation of the IP 106, 107 . IKEPP interacts constitutively with the IP but upon agonist activation, this interaction is substantially increased coinciding with increased IP-induced phosphorylation of IKEPP 107 . While the identity of the IP-induced target sites of phosphorylation within IKEPP remain to be identified, at least 6 potential phosphorylation sites within IKEPP have been proposed 130 .
IKEPP was originally identified in the kidney and gastro-intestinal system but, to date, there is no evidence of its expression in other tissue types 123, 130, 131 . As stated, prostacyclin is widely implicated in the regulation of renal hemodynamics and the IP is expressed in renal tubules and in the cortex 9, 10, 132 . Furthermore, prostacyclin is increasingly implicated in regulating renin release and in the development of renovascular hypertension-associated with obstructive vascular disease, including atherosclerosis 4, 25 . A potential role for the interaction of the IP with IKEPP in renal hemodynamics is indicated by the colocalization of IKEPP and the IP to the epithelial lining of the distal and, to a lesser extent, the proximal renal tubules 107 . In addition, consistent with the discovery of the expression of IKEPP in vascular endothelial cells, IKEPP co-localizes with the IP; is found therein in immune-complexes with the IP and, functionally, it plays a key role in IP-mediated endothelial cell migration and in vitro angiogenesis 107 . Collectively, these studies point to a novel, previously undiscovered role for the IP/IKEPP interaction within the vasculature and potentially in CVD that merits further investigation.
Summary/Conclusions:
Collectively, it is evident that significant advances have been made in identifying novel proteins and associated-pathways that influence the prostacyclin-IP axiom, providing new mechanistic insights into prostacyclin's role in maintaining vascular integrity. Armed with this knowledge, it provides new pathways regulated by the cardio-protective prostacyclin that may be targeted potentially offering novel therapeutic approaches in treating many aspects of CVD or indeed in other conditions, such as pulmonary arterial hypertension (PAH) or renovascular hypertension, in which aberrant prostacyclin signalling and function is strongly implicated. At the genomic/transcriptional level, key factors including the female hormone estrogen and low serum-cholesterol already known to play critical roles within the CV system, in particular in cardio-protection and in re-endothelialization, also up-regulate expression of the IP. In the interests of "gender balance", a remaining question worthy of investigation is what the impact of male hormones such as dihydrotestosterone on PTGIR/IP expression levels might be? Critically, the studies outlined herein provide a detailed molecular and genetic basis for understanding the main transcriptional factors determining expression of the IP within the vasculature and elsewhere. Furthermore, at the genomic level, several single nucleotide polymorphisms (SNPs) have recently been identified in the 5' flanking region of the PTGIR 31, 133 but it is unknown whether such SNPs may also contribute to population variations in IP expression levels and/or to predisposition to CVD/CAD. Through the many recent advancements outlined in this review, greater meaning and interpretation of such genome-wide association studies can also be garnered. Three-dimensional representation of the human IP, depicting the seven transmembrane (TM) domains, TM1 to TM7, and the alpha-helical 8 domain (α-H8). The structural prediction was generated by online submission to the iterative TASSER (I-TASSER) algorithm, that builds three-dimensional protein structure models based on multiple threading consensus target-to-template alignments by LOMETS
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Figure 2: Structural organization & Basal Transcriptional Regulation of the human Prostacyclin Receptor gene (PTGIR). Panel A:
The human prostacyclin receptor gene (PTGIR), located on chromosome 19q13.3, is composed of 3 exons separated by 2 introns (I1 and 12). Exon (E)1 encodes 52 bp of 5' untranslated region (UTR) sequence and is located at nucleotides -772 to -824, relative to the translational initiation codon (at +1). E2 encodes 12 bp of 5' UTR and the coding sequence for the translational initiation codon (ATG) through to amino acid 256 within TM6 of the IP ( i.e., nucleotides +1 to +767) and E3 encodes aa 256 -383 corresponding to TM6 through to the C-terminal residue (i.e., nucleotides +767 to +1149) in addition to the 3' UTR. 
Figure 5. SREBP1-mediated increases in PrmIP-directed gene expression. Panel A:
Immunofluorescence microscopy of 1° HUVECs cultured for 24 hr in high, normal or low serum-cholesterol and immunolabeled with anti-IP sera and Alexa Fluor 488-conjugated anti-rabbit IgG (green), followed by counterstaining with DAPI (blue). In low serum-cholesterol, IP expression is substantially increased. Panel B: In conditions of low-serum cholesterol, the SREBP1 precursor protein is transported to the Golgi apparatus where it is first cleaved by site-1 protease (S1P) (scissors) and then by S2P (scissors). The liberated, transcriptionally active basic helix-loop-helix (bHLH)-LZ domain of SREBP1 travels to the nucleus and directs the transcription of target genes through binding to cis-acting serum response elements (SREs) within their specific promoter regions. Panel C: In low serumcholesterol, IP mRNA levels and PrmIP-directed gene expression are significantly increased through a transcriptional mechanism involving binding of Sp1 and SREBP1, but not SREBP2, to their adjacent consensus cis-elements within the core PrmIP promoter. Presented data was adapted from Turner & Kinsella, 2012 92 . 
Figure 7. Model of the interaction of PDZK1 with the IP and its role in endothelial cell migration & in vitro angiogenesis. Panel A:
In the absence of agonist, PDZK1 is constitutively associated in a complex with the IP, where PDZK1 is either not phosphorylated or basally hypo-phosphorylated. On agonist (cicaprost) stimulation: (i) the IP undergoes an agonist-induced conformational activation leading to dissociation of PDZK1; (ii) Released PDZK1 is then subject to enhanced IP induced cAMP-dependent PKA phosphorylation at Ser 505 , and (iii) this enhanced or nett hyper-phosphorylated PDZK1 triggers its re-association with the IP. The re-association of PDZK1 and IP is coincident with regulated (iv) dephosphorylation of PDZK1 and its return to basal/hypo-phosphorylated levels. Consistent with this model, the phospho-defective PDZK1 S505A is found in a constitutive complex with the IP and undergoes agonist-induced dissociation but cannot undergo phosphorylation-induced re-association in response to receptor activation. In contrast, the phospho-mimetic PDZK1 S505D mimics the hyper-phosphorylated protein state (state iii), leading to sustained interaction with the IP. Panel B: Agonist activation of the IP, SR-B1 and VEGFR leads to enhanced endothelial cell migration and in vitro angiogenesis/tube formation. HDL/SR-B1-, but not VEGF/VEGFR-, mediated endothelial cell-migration is dependent on its interaction with PDZK1. Cicaprost activation of the IP promotes endothelial cell migration and tube formation in a PDZK1-dependent mechanism, where siRNA disruption of PDZK1 inhibits both cicaprostand HDL-, but not VEGF-, induced endothelial cell responses. Presented data was adapted from Turner et al., 2011 106 .
Figure 8: Differential Modulation of the Interaction of IKEPP & PDZK1 with the IP.
In the absence of agonist, both IKEPP and PDZK1 are constitutively associated in a complex with the IP where these interactions are largely dependent on PDZ domain 1 (PDZD1) and, to a lesser extent, on PDZD2 of IKEPP or, in the case of PDZK1, on PDZD3 and, to lesser extent, on PDZD1 and on PDZD4. Upon cicaprost stimulation (10 min; CICA), the association of IKEPP and PDZK1 with the IP is differentially modulated. Specifically, the association of IKEPP with the IP is enhanced in response to receptor activation, an effect that is abrogated by the selective IP antagonist RO1138452 and the combined activity of the PKA and PKC inhibitors, H-89 and Gö6983, respectively. On the other hand, in response to cicaprost (10 min) stimulation, there is a transient disassociation of PDKZ1 from the IP complex and this occurs due to IP-induced PKA phosphorylation of Ser 505 within the C-terminal regulatory domain of PDZK1. Cicaprost-stimulation promotes endothelial cell migration and in vitro angiogenesis, effects that are impaired by the IP antagonist RO113845 or siRNA-disruption of IKEPP or PDZK1 expression. Presented data was adapted from Reid et al., 2012 107 .
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